NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
Clinical Trials
6 trialsNCT06853678 2025-03-03
Second-line Immunotherapy for ES-SCLC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Recruiting
NCT03095612 2024-06-13
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT03193437 2023-02-16
SELECT
Georgetown University
Phase 2 Terminated
NCT03466827 2018-03-15
TET-SEL
Rigshospitalet, Denmark
Phase 2 Unknown
NCT02351505 2016-05-16
Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated